Evening aspirin intake results in higher levels of platelet inhibition and a reduction in reticulated platelets - a window of opportunity for patients with cardiovascular disease?

Diemen, Jeske Joanna Katarina van; Madsen, Milou Cecilia; Vrancken, Peeters M-Jt; Bie, K. De; Bom, Johanna G. van der; Veen, Gerrit; Bonten, Tobias N; Fuijkschot, Wessel W.; Smulders, Yvo M.; Thijs, Abel

doi:10.1080/09537104.2020.1809643

Cited by 3 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies of aspirin in platelet inhibition 57 underscore another point: the better time for treatment should be interpreted in the context of what was measured. For example, whereas morning dosing of proton pump inhibitors (PPIs) was more effective for activity-induced gastroesophageal reflux, evening dosing was more effective for nocturnal reflux 58 .…”

Section: Discussionmentioning

confidence: 99%

Factors Associated with Medicine Timing Effects: A Meta-analysis

Ruben

Francey

et al. 2021

Preprint

View full text Add to dashboard Cite

Importance Clinical evidence suggests that the time of day of treatment can affect outcomes in many different diseases, but this information is dispersed, imprecise, and heterogeneous. Consequently, practice guidelines and clinical care recommendations seldom specify intervention time. Objective To understand the sources of variability and summarize clinical findings on the time of day effects of medicine. Data Sources A systematic search of Pubmed, Google Scholar, and ClinicalTrials.gov for chronotherapy OR time of administration. Study Selection Any clinical study since 2000, randomized or observational, that compared the effects of treatment at different times of day. We included pharmacologic or surgical interventions having at least one continuous outcome. Data Extraction and Synthesis For selected studies, we extracted the mean and variance of each time-of-day treatment group. From these, we computed the standardized mean difference (SMD) as the measure of timing effect. Where a study reported multiple outcomes, we selected a single outcome based on a defined order of priority. Main Outcomes and Measures We estimated overall pooled effect size and heterogeneity by a random effects model, followed by outlier detection and subgroup analyses to evaluate how study factors, including drug, design, outcome, and source, associate with timing effect. Results 78 studies met the inclusion criteria, comprising 48 distinct interventions over many therapeutic areas. We found an overall effect of time on clinical outcomes but with substantial heterogeneity between studies. Predicted effects range from none to large depending on the study context. Study size, registration status, and source are associated with the magnitude of effect. Larger trials and those that were pre-registered have markedly smaller effects, suggesting that the published record overstates the effects of the timing of medicine on clinical outcomes. In particular, the notion that antihypertensives are more effective if taken at bedtime draws disproportionately from one source in the field, which consistently detects larger effects than the community average. Lastly, among the most highly studied drug timing relationships, the aspirin anti-clotting effect stands out, consistently favoring evening over morning dosing. Conclusions and Relevance While accounts of drug timing effects have focused on yes/no, appreciating the range of probable effects may help clarify where circadian medicine meets the threshold for clinical benefit.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors Associated with Medicine Timing Effects: A Meta-analysis

Ruben

Francey

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

Chrono-pharmacology-based antiplatelet therapy for acute myocardial infarction

Tual‐Chalot

Stellos

2022

European Heart Journal

View full text Add to dashboard Cite

COVID-19: Sleep, Circadian Rhythms and Immunity – Repurposing Drugs and Chronotherapeutics for SARS-CoV-2

2021

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has affected nearly 28 million people in the United States and has caused more than five hundred thousand deaths as of February 21, 2021. As the novel coronavirus continues to take its toll in the United States and all across the globe, particularly among the elderly (>65 years), clinicians and translational researchers are taking a closer look at the nexus of sleep, circadian rhythms and immunity that may contribute toward a more severe coronavirus disease-19 (COVID-19). SARS-CoV-2-induced multi-organ failure affects both central and peripheral organs, causing increased mortality in the elderly. However, whether differences in sleep, circadian rhythms, and immunity between older and younger individuals contribute to the age-related differences in systemic dysregulation of target organs observed in SARS-CoV-2 infection remain largely unknown. Current literature demonstrates the emerging role of sleep, circadian rhythms, and immunity in the development of chronic pulmonary diseases and respiratory infections in human and mouse models. The exact mechanism underlying acute respiratory distress syndrome (ARDS) and other cardiopulmonary complications in elderly patients in combination with associated comorbidities remain unclear. Nevertheless, understanding the critical role of sleep, circadian clock dysfunction in target organs, and immune status of patients with SARS-CoV-2 may provide novel insights into possible therapies. Chronotherapy is an emerging concept that is gaining attention in sleep medicine. Accumulating evidence suggests that nearly half of all physiological functions follow a strict daily rhythm. However, healthcare professionals rarely take implementing timed-administration of drugs into consideration. In this review, we summarize recent findings directly relating to the contributing roles of sleep, circadian rhythms and immune response in modulating infectious disease processes, and integrate chronotherapy in the discussion of the potential drugs that can be repurposed to improve the treatment and management of COVID-19.

show abstract

Evening aspirin intake results in higher levels of platelet inhibition and a reduction in reticulated platelets - a window of opportunity for patients with cardiovascular disease?

Abstract: Evening aspirin intake results in higher levels of platelet inhibition and a reduction in reticulated platelets-a window of opportunity for patients with cardiovascular disease?, Platelets,

Cited by 3 publications

References 40 publications

Factors Associated with Medicine Timing Effects: A Meta-analysis

Factors Associated with Medicine Timing Effects: A Meta-analysis

Chrono-pharmacology-based antiplatelet therapy for acute myocardial infarction

COVID-19: Sleep, Circadian Rhythms and Immunity – Repurposing Drugs and Chronotherapeutics for SARS-CoV-2

Contact Info

Product

Resources

About